Abstract
Background: Brivaracetam (BRV) is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand. Although structurally related to levetiracetam, BRV has higher brain permeability, faster brain SV2A occupancy, and more rapid onset of action. These properties make BRV potentially an ideal compound in the emergency setting. The aim of our study was to systematically review the evidence about the clinical efficacy and tolerability of BRV in the treatment of SE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
